With Additional Data Lilly Aims Broader Use For Verzenio In Post-Surgery Breast Cancer Setting

• Eli Lilly And Co (NYSE: LLY) announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer.

• The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up.

• Also read: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage.

• In 2020, The monarchE trial hit statistical significance after a median of 15.5 months follow-up. Verzenio’s addition to post-surgery endocrine therapy significantly cut the risk of invasive cancer recurrence or death by 25%, regardless of Ki-67 status.

• Now, investigators have followed patients for a median of 42 months, coming to the second preplanned interim analysis of patient survival. Nearly all patients had already come off the two-year treatment period.

• In the overall population, the Verzenio group had a 33.6% reduced risk of developing invasive disease recurrence or death over the control arm, which got endocrine therapy alone.

• Adjuvant Verzenio also reduced the risk of developing the metastatic disease by 34.1%.

• Price Action: LLY shares are up 0.26% at $369.25 on the last check Wednesday.

See more from Benzinga

• European Official Says COVID-19 Booster Uptake Disappointing In The Region

• Trump's Billionaire Neighbor Warned The Economy Was In An 'Omnibubble,' He Was Right

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.